OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Blau on a Research-Based Approach to Meet OCM Requirements

October 27th 2017

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. Ruiz on the HIV-Oncology Clinic Program

October 27th 2017

Marco Ruiz, MD, associate physician, Moffitt Cancer Center, discusses HIV-Oncology Clinic at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

October 26th 2017

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma

October 26th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

October 26th 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

October 26th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Dr. Mims on the Current Challenges With Myelofibrosis

October 26th 2017

Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.

Dr. Mehta Discusses Combinations in Multiple Myeloma

October 26th 2017

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Dr. Cohen Discusses Entrectinib in Head and Neck Cancer

October 26th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Dr. Uzzo Discusses the Role of Surgery in Kidney Cancer

October 26th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

October 26th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

Dr. Guitera on the RADICAL Trial for Melanoma

October 25th 2017

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL

October 25th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Mitchell on Clinical Trials Exploring Medical Marijuana for Patients With Cancer

October 25th 2017

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.

Dr. Winter on Checkpoint Inhibitors for Hodgkin Lymphoma

October 25th 2017

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Dr. Schaider Discusses Drug Resistance for Melanoma

October 25th 2017

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

October 24th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

October 24th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

October 24th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Dr. Burris on the Potential of PARP Inhibitors in TNBC

October 24th 2017

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).